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ABSTRACT 
Introduction 
Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 
15% of all cases of leukemia in adults. CML treatment is mainly based on tyrosine kinase 
inhibitors (TKIs). Current TKIs approved as first line treatments are imatinib or second-
generation TKIs such as dasatinib and nilotinib. Overall, TKIs have modified the natural 
progression of CML, prolonging survival. As CML has progressively switched from a 
fatal to a “chronic” pathology, time-limited clinical trials may not evaluate such long-
term outcomes adequately. On the brink of the commercialization of generic imatinib, 
this thesis examines a decade of CML management in the real clinical practice, focusing 
on treatment effectiveness, therapeutic switches, and adverse effects (AEs). 
Methods 
A retrospective cohort study was performed on all CML patients followed up in the Local 
Health Authority of Treviso (Region of Veneto, Italy) between 2005 and 2015. Data were 
captured integrating both administrative databases and physicians’ patient record. The 
therapeutic pattern was evaluated separately according to CML phase at diagnosis, 
considering frontline treatments, occurrence of treatment switches and their causes. For 
patients diagnosed in chronic phase (CP), the effectiveness of different frontline TKIs 
was assessed using an intention-to-treat approach, considering the achievement of 
complete hematologic, cytogenetic and molecular response. Occurrence of AEs among 
different frontline TKIs treatments was compared. All data and statistical analysis were 
performed using the software STATA version 14.  
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Results 
A total cohort of 119 CML patients was examined; the majority of them were diagnosed 
in CP (n=97). 60% of subjects were asymptomatic at diagnosis; even when present, 
symptoms were mainly unspecific. Imatinib was the most common first line treatment for 
CP subjects (n=73); among second generation TKIs, only nilotinib was used as first line. 
Nilotinib proved more effective than imatinib, both considering achievement of responses 
and treatment switches; 28 CP-CML patients with frontline imatinib needed to switch, 
mainly due to intolerance but there were no therapeutic switches in patients with frontline 
nilotinib. AEs were common; in particular, osteoarticular pain was significantly more 
frequent for imatinib compared to nilotinib (50 out of 73 vs 2 out of 8, respectively; 
p=0.02).  
Conclusion 
Although based on a small population, this study shows the importance of choosing 
the most appropriate frontline treatment, in order to allow rapid disease control. Results 
indicate a superiority of nilotinib as first line therapy for CP-CML, both in terms of 
effectiveness and of treatment switches and AEs occurrence. While this might be seen as 
an argument to use nilotinib first line, it might also argue strongly for the continued use 
of imatinib first line, reserving nilotinib for imatinib intolerant or resistant patients. AEs 
remain a major concern, highlighting the importance of close monitoring of patients. A 
full health economic evaluation is required to determine the most cost effective care 
pathways using these expensive drugs.  
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1. INTRODUCTION 
1.1. Definition of Chronic Myeloid Leukemia 
The term leukemia indicates a group of clonal bone marrow malignancies 
characterized by an increase in the numbers of abnormal white blood cells 1. 
Different forms of leukemia exist, according to the type of white blood cells 
involved. The four main types of leukemia include acute lymphoblastic leukemia, 
acute myeloid leukemia, chronic lymphocytic leukemia and chronic myeloid 
leukemia (CML); other less common kinds of leukemia are known, as well 2.  
In particular, CML is characterized by a deregulated overproduction 
of myeloid cells by the bone marrow, with a subsequent increase in the 
concentration of both mature granulocytes -neutrophils, eosinophils and basophils- 
and their precursors in the blood circulation.  
1.2. Epidemiology of CML: incidence, prevalence and survival 
CML accounts for around 15% of all cases of leukemia in adults 3,4, and presents a 
crude annual incidence of 0.7 – 1.0 cases per 100,000 people 5. The incidence is far 
lower among children, and is estimated to be around 0.6–1.2 cases per 1,000,000 
children/year 5. 
Data coming from different European registries show a correlation between 
increasing age and CML incidence, with a median age at onset estimated around 
57- 60 years and a male/female ratio of 1.2 – 1.7 5 (figure 1.1).  
No variation in CML incidence has been detected over time; on the other hand, 
the prevalence of CML has significantly increased and is now estimated to be 10 – 
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12 cases/100,000 people 5-7  (figure 1.2). Such an increase in prevalence is mainly 
attributable to changes in therapeutic management of CML, that have massively 
prolonged patients’ overall survival (OS). Before the ‘90s, in fact, only 20-40% of 
patients affected by CML remained alive at 5 years from diagnosis 8, with more 
than 85% of patients dying within the first 8 years from CML onset 9. 
With the advent of interferon-α (IFNα)-based therapy and allogeneic 
hematopoietic stem cell transplantation (HSCT) in the ‘80s, the 8-years survival 
rapidly improved, reaching 65% in 2000 9.  
However, it was the introduction of Tyrosine Kinase Inhibitors (TKI)-based 
therapies, in 2001, that allowed the greatest improvement in CML prognosis, 
reaching an 8-year survival that is now estimated around 87% and that continues to 
improve, thanks to the use of second- and third-generation TKIs 9. 
 
Figure 1.1: Trend of annual incidence of CML among different age groups. Data are obtained 
from the Swedish Cancer Registry for the years 2002 – 2012 
(www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish) 5 
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Figure 1.2: Changes in survival of patients with CML over years: the German CML-Study Group 
experience 10 
 
1.3. Pathogenesis and risk factors 
Both patients’ related and environmental risk factors have been associated with 
the onset of CML. Among unmodifiable patient’s related characteristics, male sex 
is a well-known risk factors, although the clear reason for its association with CML 
onset is still unclear 11. History of previous malignancies has been associated to an 
increased risk of CML, as well, probably in force of a personal enhanced 
susceptibility towards neoplastic disorders 12. Considering compartmental 
modifiable risk factors, attitude and intensity of smoking, as well as poor physical 
activity, have been positively associated with higher risk of CML onset 13. Among 
environmental factors, exposition to ionizing radiation has been detected as one of 
the major causes of CML, based on observations on survivors of the nuclear 
bombing 11.  
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Independently for the causal risk factor, unlike many other malignancies that can 
originate from the accumulation of different mutations, CML is invariably related 
to a unique type of mutation, i.e. the BCR-ABL fusion gene on the abnormal 
Philadelphia (Ph) chromosome. The Ph chromosome was first discovered and 
described in 1959 by David A. Hungerford from Fox Chase Cancer Center (then 
the Institute for Cancer Research) and Peter Nowell from the University of 
Pennsylvania School of Medicine and was therefore named after the city in which 
both facilities are located.14. 
This abnormal chromosome originates from the reciprocal translocation 
t(9;22)(q34;q11) between chromosome 9 and 22 15. In particular, the upstream part 
of the BCR gene located on chromosome 22 fuses to the downstream part of the 
ABL gene located on chromosome 9 16, therefore creating a new fusion gene named 
BCR-ABL (figure 1.3).  
 
Figure 1.3: The chromosomal translocation and the generation of the Philadelphia chromosome 17 
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1.3.1. Physiological role of Abl and Bcr proteins 
Physiologically, the ABL gene encodes for a non-receptor tyrosine kinase, whose 
activity is carried by the SH1 domain 18. This kinase can have both cytoplasmic and 
nuclear localization. In the cytoplasm, Abl mediates functions including integrin 
signaling and cytoskeletal molding, whereas in the nucleus it is involved in the 
regulation of the cell cycle and in responses to genotoxic stress 19-22. 
Normally, the kinase activity of Abl is strictly controlled, through motifs in the 
N-terminal region of the protein that tightly regulate its phosphorylation. Loss of 
this N-terminal region – as occurs in the Bcr-Abl fusion protein- results in an 
uncontrolled constitutively activated kinase activity with a strong oncogenic 
potential 23-26. 
Like the Abl protein, also the Bcr protein physiologically has both cytoplasmic 
and nuclear localization 27, and it possesses a variety of active motifs involved in 
phosphorylation and guanosine triphosphate binding 28-32.  
In particular, Bcr interacts with G proteins and with xeroderma pigmentosum 
gene products, therefore being probably involved in intracellular signaling, 
cytoskeletal organization, cell growth, and normal development, as well as in DNA 
repair mechanisms 29-31.  
The first exon of the BCR gene encodes for one of the most important parts of 
the Bcr protein. This exon encodes for a serine and threonine kinase, which can 
mediate both auto- and allo-phosphorilation, therefore, being involved also in signal 
propagation. This exon appears to be of extreme importance, since it is the only 
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exon that is always present in the Bcr-Abl proteins and it is considered pivotal for 
the oncogenic activity of this fusion protein 31,33,34.  
1.3.2. The structure of the Bcr-Abl fusion protein 
Following a chromosomal reciprocal translocation, the juxtaposition of the BCR 
and ABL genes occurs, therefore generating a fusion gene, which consists of the 5’ 
end of the BCR gene fused to the 3’ end of the ABL gene.   
Of note, the position of the BCR and ABL genomic breakpoints is extremely 
variable (figure 1.4). In particular, the BCR gene presents three main breakpoints: 
the major breakpoint cluster region (M-bcr), located between exon 6 and 12; the 
minor one (m-bcr) in the first intron of the gene; and the micro-bcr (μ-bcr), a third 
breakpoint cluster further upstream in the BCR gene. Therefore, three different 
fusion proteins may occur, named p210Bcr/Abl and p190Bcr/Abl and p230Bcr/Abl, 
respectively. In addition, other rare breakpoint cluster region on BCR gene have 
been observed 35-37.  Instead, on chromosome 9, only one breakpoint in the ABL 
gene is usually observed. This breakpoint, located between exon 1 and 2, generates 
a constant ABL-portion, that can associate with one of the three BCR-portions, 
therefore leading to different BCR-ABL fusion genes 38. 
Around 95% of patients present the M-bcr breakpoint, encoding for the b2a2 or 
b3a2 transcripts (also referred to as e13a2 or e14a2) and producing the p210 fusion 
protein 39,40. On the other hand, less than 5% of CML patients present the m-bcr 
breakpoint, which results in the e1a2 transcript encoding for the p190 protein 39. 
The μ-bcr breakpoint producing the e19a2 transcript and the p230 fusion protein is 
instead much more infrequent, and was initially associated only with neutrophilic 
  
15 
 
CML 41; however, some studies revealed that  μ -bcr is present also in few cases of 
classical CML and acute myeloid leukemia 42,43. 
Other transcripts such as e2a2, e1a3, e6a2, e13a3 (b2a3), and e14a3 have been 
reported as well, although they occur quite rarely 44. 
 
 
 
Figure 1.4: The BCR and ABL genes, the main breakpoint regions and the corresponding BCR-
ABL transcripts 39   
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1.3.3. Pathogenic mechanisms mediated by the Bcr-Abl fusion protein 
The Bcr-Abl fusion protein is reported to be involved in a variety of cellular 
pathways among which changes in growth factor dependence, apoptosis, 
proliferation and cell adhesion, therefore sustaining granulocytes hyper-
proliferation and mediating leukemia pathogenesis 45. 
One of the most important pathway involved in CML pathogenesis is the 
JAK/STAT signalling pathway. Bcr-Abl kinase activity enhances in fact 
JAK2/STAT activation, therefore promoting cell growth and cell survival 46. 
Besides the JAK/STAT pathway, Bcr-Abl can stimulate PI3K proteins 
signalling, therefore influencing the activities mediated by these proteins among 
which modulation of transcription factor activation, regulation of cell growth and 
survival, and inhibition of cell death 47. In addition, PI3K activation also stimulates 
the mTOR pathway, which is involved in controlling protein synthesis, cell growth 
and autophagy 48. 
Cell growth is further promoted also by the Bcr-Abl mediated stimulation of the 
Ras GTPases/MEK kinases 49,50.  
Besides promoting cell proliferation, Bcr-Abl can also prevent cell death, mainly 
by increasing the expression of the anti-apoptotic proteins Bcl2 and Bcl-XL 51.  
Furthermore, Bcr-Abl mediates the phosphorylation of the pro-apoptotic protein 
Bad, thereby restricting Bad to the cytoplasm and preventing its pro-apoptotic 
action 52.  
 
  
17 
 
1.4. How to diagnose CML 
CML is a subdual disease, since around 40% of subjects are asymptomatic and are 
diagnosed through a laboratory test performed by chance 53. Even if present, 
symptoms are mainly unspecific, and include fatigue, weight loss, abdominal 
fullness, bleeding, purpura, splenomegaly, leucocytosis, anaemia, and 
thrombocytosis 3,54. 
The suspect of CML usually arises after an abnormally high granulocyte count 
coming from a full blood cell count analysis. In this case, the identification of the 
Ph chromosome through karyotyping and the detection of the BCR-ABL gene by 
quantitative PCR are used to confirm the diagnosis of CML 40,54.  
However, what’s worth noting is that the presence of the BCR-ABL transcript 
can and has been detected also in healthy subjects not affected by CML 55. 
A possible explanation is that the generation of certain fusion genes, such as 
those implicated in CML pathogenesis, is not rare in hematopoietic cells: however, 
in the majority of cases, these cells do not develop the additional mutations that are 
necessary for the neoplastic process sustaining CML pathogenesis 56.  
However, it must be specified that the BCR-ABL signal coming from the 
eventual detection of such fusion gene in healthy patients is very low, with the 
possibility of false-positive diagnosis being therefore practically irrelevant 56.   
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1.5. Progression of the pathology 
CML staging includes three distinct phases. Around 85% of patients with CML are 
diagnosed in chronic phase (CP), which is the mildest phase 3.  Without therapeutic 
intervention, CML progresses from CP to the accelerated phase (AP) and to the 
final blast crisis (BC) 40,54. 
The progression from one phase to another is linked with increase in severity 
and decrease in life expectancy. In fact, following advancement of the disease, the 
leukemic cells progressively lose their ability to differentiate into mature 
granulocytes, therefore resulting in the overexpression of primitive immature 
cells40.  
The massive presence of immature cells and the lack of proper differentiation 
further leads to acute events of infection, thrombosis and anaemia, which nearly 
inevitably leads to patient’s death 57. 
Disease progression can be monitored through the analysis of the blast cell count 
in the peripheral blood.  
In particular, according to the European LeukemiaNet (ELN) guidelines,  
“AP is defined by 15 to 29 % blast cells or by 30 to 49 % blast cells plus 
promyelocytes in blood or marrow or by platelet count <100 × 109/L or by a clonal 
chromosome abnormality in Ph + cells. On the other hand, BC is defined by a blast 
cells percentage ≥30 % in blood or marrow or by blast cells involvement of non 
hematopoietic tissues, excluding liver and spleen” 58,59. 
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The ELN criteria are slighlty different from those indicated by the World Health 
Organisation, which defines AP with blast cells percentage of 15-19% and BC with 
percentages ≥20 % 60 (figure 1.5).  
In addition, the detection of additional clonal chromosomal abnormalities (ACA) 
- a phenomena known as clonal evolution- is recognized as a sign of therapeutic 
failure and of disease progression 59. 
It must be specified that both myeloid and lymphoid phenotypes can be present 
in BC, with myeloid-BC being two times more frequent compared to lymphoid-  
BC 61. 
 
Figure 1.5: Definition of accelerated phase (AP) and blast crisis (BC) according to the European 
LeukemiaNet (ELN) criteria vs the World Health Organisation (WHO) criteria 59 
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1.6. Assessment of patient’s risk of progression 
As previously said, CML phase at entry is a fundamental prognostic factor for 
patient’s survival.  
Besides phase at entry, patient’s specific risk factors at baseline are extremely 
important, since they seem to impact even more than therapeutic treatment on CML 
prognosis 62.  
To assess them, three main risk scores are available, which have been developed 
through years according to the availability of different therapeutic treatments and 
to the on-going knowledge of the pathology (table 1.1).  
In particular, the first two scores -Sokal and Euro- 63,64 were developed in the 
“pre-TKI” era, when only IFN and/or hydroxyurea (HU) /busulfan were available, 
and the link between BCR-ABL gene and CML pathogenesis were still unknown.  
These scores have represented an extremely important tool in the estimation of 
prognosis and survival of patients treated with traditional chemotherapy or 
interferon, respectively. 
The only score elaborated after the advent of TKIs is the EUTOS 65. However, 
even in the era of TKIs, the Sokal score is still considered an extremely predictive 
tool in clinical practice, since it resulted to significantly correlate with response to 
TKIs, with survival, and also with treatment-free durable molecular response 66.  
According to the ELN recommendations, all three scores are useful to assess 
patient’s risk 59. In particular, their combinatorial use in clinical practice may be 
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crucial to identify those patients who would benefit the most from a first line 
treatment with a second-generation TKI 67. 
 
Score and study Calculation Risk definition 
Sokal 
Sokal et al. 1984 
Exp 0.0116 × (age − 43.4) + 0.0345 
× (spleen − 7.51) + 0.188 × [(platelet 
count ÷ 700) − 0.563] + 0.0887 × (blast 
cells − 2.10) 
Low risk: <0.8 
Intermediate risk: 0.8-
1.2 
High risk: >1.2 
Euro 
Hasford et al. 
1998 
0.666 when age ≥50 y + (0.042 × 
spleen in cm) + 1.0956 when platelet 
count >1500 × 109L + (0.0584 × blast 
cells) + 0.20399 when basophils >3% + 
(0.0413 × eosinophils) × 100 
Low risk: ≤780 
Intermediate risk: 781-
1480 
High risk: >1480 
EUTOS 
Hasford et al. 
2011 
Spleen in cm × 4 + basophils × 7 
Low risk: ≤87 
High risk: >87 
Table 1.1: Calculation and stratification of the Sokal, Hasford and EUTOS risk scores 63-65 
 
Besides these three risk scores, the presence of ACAs at diagnosis is clearly 
recognized as an important prognostic factor 68-70. In a study on imatinib-treated 
patients, subjects carrying ACAs at diagnosis had a significantly lower 5-year 
failure free survival (FFS) rate compared to patients with no ACAs (52% vs 84%)71.  
Similarly, presence of ACAs at baseline has been associated with lower rates of 
treatment responses 69. In particular, deletion and variant translocations of the 
chromosome 9 seem to have no significant impact on prognosis, whereas 
abnormalities including trisomy 8, trisomy Ph (+der(22)t(9;22)(q34;q11)), 
isochromosome 17 (i(17)(q10)), trisomy 19, and ider(22)(q10)t(9;22)(q34;q11) 
have been associated with adverse prognosis 68,69,72. 
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The development of ACA during treatment- named clonal evolution- is instead 
considered a sign of disease progression, as reported in the previous paragraph.  
Furthermore, also the variability in BCR-ABL transcripts seems to affect CML 
prognosis. Focusing on the most common transcripts generated by the major 
breakpoint, the e14a2 transcript appears to be associated with a better response to 
imatinib compared to the e13a2 transcript 73-75. This could be attributable to the 
differences in term of secondary structure elements and amino acidic sequences 
between the two transcripts that could exert different activities in mediating signal 
transduction pathway 76. The e1a2 transcript coding for the p190 protein, although 
infrequent in patients, was found to be associated with poor prognosis and poor 
response to TKI therapies. Patients carrying this transcript are therefore identified 
as high-risk patients, for whom close monitoring and evaluation of HSCT eligibility 
are recommended 44.  Similarly, variability in hematological and cytogenetic 
responses to TKIs and aggressiveness in clinical course have been described for 
e19a2 and e6a2 transcripts 77-82. 
Besides these well-recognized risk factors, the role of several other baseline 
factors is under investigation.  Among them, the BCR-ABL level at diagnosis could 
represent another prognostic factor, although its real clinical impact is still      
unclear 83. According to a study conducted on patients treated with imatinib, higher 
levels of BCR-ABL transcripts at diagnosis were associated with lower rates of FFS 
and progression free survivals (PFS) 84. However, other studies did not support this 
correlation 85.  
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In addition, the levels of expression of certain cellular protein involved in the 
drug transport, such as the organic cation transporter 1 (OCT1), have been 
associated with CML prognosis. In fact, OCT1 is the major active influx pump for 
imatinib; for patients treated with this TKI, high levels of expression of OCT1 have 
been connected to higher response and better survival 86,87. However, at the moment 
no test is clinically available for the assessment of OCT1 expression levels in CML 
patients, and the real clinical impact of OCT1 on responses to first and second 
generation TKIs is still unclear. 
Furthermore, also the gene expression profile, the polymorphisms of genes 
coding for proteins involved in drug metabolism and transport, and in apoptosis, 
and the presence of low-level BCR-ABL mutations, have been considered as 
potential risk factors, whose real clinical impact must be clarified 70.  
 
1.7. Treatment 
1.7.1. History of CML therapeutic approach 
First reports of cases of splenomegaly associated with abnormally high 
leukocyte count date back to the 1840s. These cases were probably examples of the 
later-discovered CML. During the 19th century, the only well-documented therapy 
in use was arsenic, which displayed good efficacy in reducing leucocytosis but had 
poor benefits on patient’s OS 88.  
Therapeutic strategies moved then to radiotherapy, and later on to busulfan, 
hydroxycarbamide, or IFN-α, which represented the most common therapeutic 
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strategies during the 20th century. These therapies however accounted for poor 
long-term survival, with more than 85% of patients dying within the first 8 years 
from diagnosis 9,88. 
The discoveries of the Ph chromosome in 1960, of the (9;22) translocation in 
1973, and of the breakpoint cluster region on chromosome 22 in 1984, deeply 
modified the therapeutic approach of CML 88. From 1980 allogenic HSCT became 
the first-choice treatment for eligible patients, with a great improve on the 8-years 
OS, that reached 65% in 2000 9,88. 
However, it was the advent of TKIs that deeply modified both the therapeutic 
approach and the prognosis of CML, overcoming all other therapeutic options and 
accounting for a long-term survival that is now comparable to that of the general 
population 9,88. 
1.7.2. The advent of Tyrosine Kinase Inhibitors (TKIs) 
1.7.2.1.First generation TKI: imatinib 
In the late 1980, using a high throughput screening techniques, scientists of 
actual Novartis pharmaceutical company discovered a lead molecule – a 2-
phenylaminopyridine-based ATP competitive inhibitor, known as ST1-571 -, that 
displayed a strong activity as ABL kinase inhibitor.  
In fact, this compound resulted to competitively bind the ATP binding site of the 
inactive conformation of the ABL protein tyrosine kinase, therefore preventing its 
switch to the active conformation and strongly inhibiting the ABL kinase activity 
89-91 (figure 1.6).  
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Figure 1.6: Mechanism of action of imatinib 92 
 
This molecule, named imatinib, was proved to inhibit cellular proliferation in an 
apoptosis-independent pathway; furthermore in vitro studies showed that imatinib 
decreased the growth of Ph positive cells colonies of about 92-98%, with no 
significant alteration on the growth of normal cells colonies 93. Besides ABL 
inhibition, this molecule resulted to be active also against other kinases (such as the 
c-kit) and against the platelet-derived growth factor receptors (PDGFR), which can 
be involved in the oncogenic pathway 91,94,95.  In addition, imatinib was seen to play 
immunomodulatory effects on T cells and antigen-presenting cells 96. Following the 
promising results of phase I and II randomized control trials (RCTs) performed on 
AP and BC CML patients treated with imatinib 600mg/day 97-100, imatinib was 
firstly approved by the FDA (Food and Drug Administration) with the commercial 
name of Glivec, for the treatment of AP and BC CML patients.  Later on, it was the 
phase III clinical trial IRIS that first demonstrated the great benefit coming from 
TKI treatment with imatinib also in CP CML 101. In this trials, imatinib at the dosage 
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of 400 mg daily was compared with the combination of IFNα and low-dose 
cytarabine -i.e. the gold standard treatment at the time- for the treatment of newly 
diagnosed CP CML patients. After a median time of 19 months of imatinib 
treatment, 96%, 87% and 76% of patients had reached complete hematologic 
response (CHR), major cytogenetic response (MCyR) and complete cytogenetic 
response (CCyR), respectively.  
The efficacy of imatinib was further confirmed in a 6-years follow-up study, 
reporting an estimated event-free survival of 83% and a percentage of intolerance-
related treatment discontinuations of 5% 102.  
According to the current ELN recommendations, imatinib should be used at an 
initial daily dosage of 400mg 59. No supporting data exist in fact for the use of high-
dose imatinib as first line treatment. The prospective TOPS (Tyrosine kinase 
inhibitor OPtimization and Selectivity) trial compared the efficacy of high dose 
(800mg/daily) vs standard dose (400mg/daily) imatinib. Although percentages of 
achievement of major molecular response (MMR) at 3 and 6 months following 
treatment beginning were higher among patients treated with high dose imatinib, 
no difference emerged in the achievement of 12-months MMR 103. Similarly, a 
study by the ELN did not show better responses among patients treated with high-
dose 104.  
Despite the efficacy of imatinib, the development of either treatment resistance 
or intolerance still represents a major concern in the treatment of CML. In the IRIS 
trial, 31% and 5% of patients were unable to achieve CCyR within 1 and 5 years of 
treatment, respectively. What’s more, 3-years treatment failure occurred in 3-7% of 
  
27 
 
patients, and 5% of patients discontinued imatinib because of severe          
intolerance 101,105.   
To overcome this problem, second-generation TKIs were developed.   
1.7.2.2.Second generation TKIs: nilotinib and dasatinib 
Second-generation TKIs were developed based on the chemical and crystal 
structure of imatinib–ABL complex (figure 1.7). In particular, a similar ATP-
competitive phenylaminopyrimidine molecule named nilotinib (brand name 
Tasigna) was designed by Novartis.   
 
Figure 1.7: Chemical structure of the three TKIs 
 
Like imatinib, nilotinib binds and blocks the ABL kinase in its inactive form, 
therefore preventing the substrate binding and the consequent catalytic action 106. 
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Compared to imatinib, crystallographic data indicate a higher affinity of nilotinib 
for the ABL kinase, therefore resulting in increased selectivity and in an 30-times 
higher in vitro efficacy on inducing Ph positive cells lysis 106-109.  
In addition, nilotinib showed good efficacy in a phase II trial conducted on 
imatinib-resistant CP patients, with percentages of 6-months MCyR and CCyR 
achievement of 48% and 31% 110.  Similarly, a phase II trial performed on imatinib-
resistant AP patients showed rates of hematologic response, CHR, MCyR and 
CCyR of 56%, 31%, 32% and 20%, respectively, with a median time to hematologic 
response of 1 month 111. What’s more important, nilotinib resulted to be effective 
in 32 out of 33 mutations leading to imatinib resistance; however, no efficacy was 
seen against the T351I mutation 107-109. 
In light of these results, the FDA finally approved nilotinib in 2007 for the 
treatment of CP and AP patients resistant or intolerant to imatinib.   
In the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials–
Newly Diagnosed Patients) phase III trial, nilotinib was further evaluated as a 
possible frontline treatment for newly diagnosed CP patients 112,113. In this trial, 
nilotinib 300mg or 400mg twice daily was compared to imatinib 400mg once daily.  
At 12 months, the rates of MMR were significantly higher among nilotinib-treated 
patients (44% for 300mg twice daily nilotinib, 43% for 400 mg twice daily nilotinib 
and 22% for 400 mg once daily imatinib, respectively). Similarly, a 4-years follow-
up of the ENESTnd study indicated significantly higher efficacy and lower rates of 
disease progression among patients treated with frontline nilotinib compared to 
imatinib, as well as fewer cases of development of BCR-ABL mutations 114.  
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Nilotinib is therefore currently approved also for the treatment of newly 
diagnosed adult patients with Ph positive CP CML.  
Besides nilotinib, another ATP-competitive, non-phenylpyrimidine-based 
compound was designed to inhibit BCR-ABL tyrosine kinase. This molecule, 
named dasatinib (brand name Sprycel, produced by Bristol-Myers Squibb), was 
actually developed as a Src-family kinases (SFKs) inhibitor and it resulted to inhibit 
different tyrosine kinases, including Src, Lck, YES, EPH receptor A 2 (EPHA2) A2 
and PDGFR. Dasatinib was also seen to bind both the active and inactive 
conformations of the ABL domain 115-117, and in vitro studies revealed a higher 
potency of dasatinib compared to imatinib in inhibiting both wild-type and 
imatinib-resistant BCR-ABL kinase, except in presence of the T315I mutation 107. 
A phase I study conducted on imatinib-intolerant or resistant patients further 
demonstrated the efficacy of dasatinib in inducing significant clinical responses 
among all BCR-ABL genotypes, excluding the T315I mutation 118.  
In light of these phase I results, different phase II studies, known as the 
SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START), were 
designed to evaluate the efficacy of dasatinib in Ph positive imatinib-intolerant or 
resistant patients. According to the START-C trial, dasatinib accounted for long-
lasting major or complete responses in high percentages of patients, independently 
from the presence of mutations leading to imatinib resistance 119. Similarly, the 
comparison of dasatinib 70mg/twice daily with imatinib 800mg in the START-R 
trial reported significantly higher percentages of CHR, MCyR and MMR among 
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dasatinib-treated patients (93% vs. 82% of CHR; 52% vs. 33% of MCyR; 16% vs. 
4% for MMR) 120.  
The START-A, the START-B and START-L trials further proved the efficacy 
of dasatinib also for AP and BC CML patients 121-123. 
Based on the results of these RCTs, the initial dose of dasatinib approved for 
CML patients with resistance or intolerance to imatinib was of 70 mg twice daily. 
However, data coming from a long-term follow-up of the phase I trial showed fewer 
adverse effects among patients treated once daily compared to patients treated 
twice-daily 118.  Therefore, two phase III trials, named CA180-034 and CA180- 035, 
were further conducted to identify the optimal dosage 124,125. In the CA180-034 trial, 
four dosages of dasatinib (100 mg once daily, 50 mg twice daily, 140 mg once daily, 
or 70 mg twice daily) were compared for the treatment of CP CML. Efficacy 
resulted to be similar among the 4 groups, although the 100 mg once daily treatment 
was associated with lower rates of toxicity and of dose interruptions 124. The 
CA180-035 trial focused instead on AP CML, and compared the 140 mg once daily 
regiment vs the 70 mg twice-daily regimen. The once-daily dose of 140 mg 
dasatinib demonstrated comparable efficacy but lower toxicity 125.  
Based on these trials, the dosage of dasatinib currently approved by the FDA is 
of dasatinib 100 mg once daily for CP patients and 140 mg once daily for AP or BC 
CML patients.  
A subsequent phase III trial named DASISION (DASatinib versus Imatinib 
Study In treatment-Naive CML patients) was performed to compare the treatment 
with dasatinib 100 mg vs imatinib 400 mg among newly diagnosed CP CML 
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patients 126.  Dasatinib resulted to be associated with significantly higher 
percentages of CCyR (83% vs 72%), and MMR (46% vs 28%) at 12 months. The 
efficacy and safety of dasatinib as first line therapy were further confirmed during 
a 24 months’ follow-up 127.  
In light of these RCTs, dasatinib is currently approved also as first line treatment 
for newly diagnosed CP-CML.  
1.7.2.3.Other TKIs approved as second or third line therapies 
As previously reported, imatinib, dasatinib and nilotinib are all approved both as 
first or second line treatments. Despite their well-documented efficacy, 
development of resistance or intolerance to all these treatments can occur.  
Bosutinib (brand name Bosulif, produced by Pfizer Inc.) is a second-generation 
TKI that acts as an inhibitor of both ABL and Src kinases. It is currently approved 
for the treatment of Ph positive CP, AP and BC CML patients, with intolerance or 
resistance to other TKIs.  In fact, RCTs demonstrated that bosutinib is effective in 
inducing durable responses, as well as in accounting for high rates of PFS and OS, 
in either second, third or fourth line treatment 128,129.  
On the other hand, no superiority of bosutinib compared to imatinib was found 
in the treatment of newly diagnosed CML patients; therefore, bosutinib is not 
indicated as first line CML treatment 130,131. 
Similarly to nilotinib and dasatinib, bosutinib resulted to be effective in most 
cases of mutations providing resistance to imatinib; however, it showed no efficacy 
towards the T315I or the V299L 128.   
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To overcome the resistance to first and second generation TKIs provided by the 
T315I mutation, a new third generation TKI named ponatinib (trade name Iclusig) 
was developed by ARIAD Pharmaceuticals. The efficacy of ponatinib in T315I-
carrying CP CML patients was first demonstrated in a phase I trial in 2010.  
The phase II PACE (Ponatinib Ph+ ALL and CML Evaluation) trial further 
confirmed the efficacy of ponatinib for the treatment of Ph positive CML or acute 
lymphoblastic leukaemia with resistance or unacceptable intolerance to dasatinib or 
nilotinib or with the presence of the T315I mutation 132. Furthermore, another phase 
II trial was performed to evaluated the efficacy of ponatinib as frontline treatment 
in newly diagnosed CP CML patients. Ponatinib confirmed its efficacy; however, 
due to the high risk of vascular thrombotic events and the availability of other 
therapeutic options for these patients, ponatinib has not been approved as first line 
treatment in T315I-free patients 133. 
In light of this study, ponatinib is currently approved at the dosage of 45 mg 
daily for the treatment of CP, AP or BC CML in patients with intolerance or 
resistance to dasatinib or nilotinib, or in patients carrying the T315I mutation.  
1.7.3. Current guidelines for pharmacological treatment of CML 
As previously discussed, the TKIs currently approved for first line CML therapy 
are the first generation TKI imatinib (Glivec; recommended dosage of 400 mg once 
daily), or the second generation TKIs nilotinib (Tasigna; recommended dosage of 
300 mg twice daily) and dasatinib (Sprycel; recommended dosage of 100 mg once 
daily) (figure 1.8). The choice of the TKI must be done according to drug 
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tolerability and safety, as well as patient’s characteristics such as age, 
comorbidities, and pattern of mutations on the BCR-ABL gene 70.  
In particular, second generation TKIs displayed higher potency and efficacy in 
RCTs; however, no solid evidence exists for the preferential choice of these 
therapies as frontline treatment of CP non-high risk patients. According to the most 
recent ELN recommendations, high-risk patients and patients diagnosed in AP or 
BC could be the groups of patients benefiting the most from a second-generation 
TKI therapy 70. 
 
Figure 1.8: Treatment recommendations according to the ELN guidelines 59 
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In case of failure or intolerance to first-line treatment, patients should be 
switched to a second-line treatment.  
Available second-line treatments include the above-mentioned TKIs, that can be 
used at the standard or at a higher dose (400mg twice daily for imatinib; 400 mg 
twice daily for nilotinib; 70 mg twice daily or 140 mg once daily for dasatinib), and 
bosutinib (500 mg once daily) 59.  
If the cause of switch is intolerance, any other available TKI can be chosen; in 
this case, a second line therapy with imatinib can be started after a frontline 
treatment with a second-generation TKI 70. 
On the other hand, imatinib should not be use as second line treatment in case of 
resistance to first line therapy. Due to the lack of studies comparing the different 
second-line TKIs, the therapeutic choice should be based on patient’s 
characteristics (age, comorbidities, side effects of first TKI), as well as on the 
presence and type of BCR-ABL kinase mutations, that can impact on the sensitivity 
towards each TKIs. In particular, the T315I mutation is sensitive only to the third-
generation TKI ponatinib (recommended dosage of 45 mg once daily) 70.  
Ponatinib can be used also in absence of this mutation, in case of failure of both 
first- and second-line treatment.  
In these cases, ELN guidelines recommend an accurate analysis of patient’s 
karyotype and of eventual BCR-ABL mutations, as well as a close monitoring of 
the patient in preparation of HSCT 70. 
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On the other hand, use of non-TKI chemotherapy is not recommended and is 
limited to few particular circumstances. In particular, the association of IFNα with 
a TKI treatment could potentially represent a valid strategy, which is still under 
investigation.  
Treatment with HU can be used for a short time before starting a TKI, until 
confirmation of CML diagnosis. Similarly, cytotoxic chemotherapy can represent a 
valid control for BC while preparing patients for HSCT 59. 
1.7.4. The role of Hematopoietic Stem Cell Transplantation 
HSCT is primarily considered as a salvage intervention: current 
recommendations advise that HSCT should be reserved for BC or for subjects who 
are resistant to at least one second-generation TKI because the chances of a 
sustained response to another TKI are negligible 134. In addition, recent studies have 
provided evidence on the superiority of HSCT compared to both dasatinib and 
nilotinib in increasing survival in adult patients with AP CML 135. 
The recommendations of limiting HSCT as salvage procedure were initially 
based on the early results of imatinib compared to previously available therapies, 
and from studies reporting an increased early mortality after HSCT 136-139. 
Nowadays mortality connected to HSCT has drastically decreased and risk score 
for transplant outcome have been implemented. Among them, the European Group 
for Blood and Marrow Transplantation (EBMT) risk score system is based on 5 
variables: donor type, disease phase, recipient age, donor/recipient sex 
combination, and interval from diagnosis to transplantation 140. In addition, 
inflammatory levels and comorbidities have been proposed as independent 
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predictors of lower survival 141. Therefore, the decision for transplantation involves 
careful balancing of the risks for HSCT against the risk for disease progression in 
each individual patient 134.  
After HSCT, patients should be monitored by Reverse Transcriptase 
Quantitative Polymerase Chain Reaction (RQ-PCR); treatment with donor 
lymphocyte infusion and/or TKI is recommended as well 59. 
1.7.5. Monitoring of responses 
According to the ELN recommendations,  
“the response to TKI is the most important prognostic factor”.  In fact, current 
guidelines “do not recommend which TKI should be used but which response 
should be achieved, irrespective of the TKI that is used” 59. 
Patient’s response to treatment is evaluated at three different levels of response, 
i.e. hematological, cytogenetic, and molecular response 142. Hematological 
response is assessed through hematochemical blood tests, considering the count of 
white blood cells, platelets and circulating blast cells 7.  
In particular, cytogenetic monitoring is based on the identification and the count 
(in percentage) of Philadelphia chromosome positive nuclei during metaphase, 
using chromosome banding analysis or fluorescence in situ hybridization (FISH) 
analysis. FISH of blood interphase cell nuclei can be used as well for the evaluation 
of cytogenetic responses 59. 
Molecular analysis is performed instead using qualitative and reverse 
transcriptase quantitative PCR, to estimate the ratio of BCR-ABL mRNA compared 
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to an internal reference gene, such as ABL, GUSB or BCR 143. Molecular results 
are indicated using the International Scale (IS) as a BCR-ABL percentage, with 
100% BCR-ABL IS corresponding to the International Randomized Study of 
Interferon and STI571 (IRIS) study standardized baseline 59. In particular, BCR-
ABL percentages of 10%, 1%, 0.1%,0.01%, 0.0032%, and 0.001% indicate a 
reduction of 1, 2, 3, 4, 4.5, and 5 logs, respectively, below the standard baseline 
used in the IRIS study 59. 
Both cytogenetic and molecular tests should be performed at different time-
milestones, and timing should be adapted according to the patient’s response to 
treatment (figure 1.9).  
 
 
Figure 1.9: Timing of cytogenetic and molecular evaluations, according to the ELN 
recommendations 59 
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The best response is defined as the achievement of both CHR, CCyR and 
complete molecular response (CMR), as reported in table 1.2.   
BCR, breakpoint cluster region; ABL, Abelson murine leukemia; mRNA, messenger 
ribonucleic acid. 
Table 1.2: Assessment response to CML treatment 7 
 
Although CHR, CCyR and MMR/CMR are the gold standard to be achieved, 
definition of optimal response and of therapeutic failure varies according to the time 
and the therapeutic line (figure 1.10).  
Different studies have independently demonstrated that achievement of optimal 
response in the earliest phases is associated with more favourable long-term 
outcomes.  
In the first study supporting this correlation, levels of BCR-ABL transcript 
< 10% at 3 months from treatment beginning resulted to be significantly associated 
with higher rates of future MCyR 144. Similarly, a later study supported the 
correlation between 5-years CCyR and levels of cytogenetic response at 3 and 6 
months 145.  
Response Assessment 
Complete hematologic 
response 
Normalization of leukocyte count (white blood cell count <10 
cells×109/L) and platelet count (platelets <10 cells×109/L), 
no immature cells or blasts in the peripheral blood, no signs 
or symptoms of disease with the disappearance of palpable 
splenomegaly 
Cytogenetic response 
% Philadelphia chromosome positive metaphases: (with a 
minimum of 20 metaphases examined) 
Minor: 35%–90% 
Partial: 1%–34% 
Major: 0%–35% (complete+partial) 
Complete: 0% 
Molecular response 
Major: ≥3 log reduction of BCR-ABL1 mRNA expression 
Complete: BCR-ABL1 mRNA expression undetectable 
by reverse-transcriptase polymerase chain reaction 
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Besides correlation with MCyR or CCyR, earlier cytogenetic and molecular 
responses have been found to be associated with OS, PFS and FFS 146,147. 
 
Figure 1.10: Definition of the responses to first and to second line TKI treatment, according to the 
ELN recommendations 59 
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Intermediate suboptimal results are instead considered as a warning; in this case, 
closer monitoring is recommended to detect eventual early signs of therapeutic 
failure 59. 
Therapeutic failures can be either primary, i.e. the patient does not achieve a 
given response at a given time, or secondary, i.e. a loss of response occurs at a 
certain time after its achievement. In both cases, the therapeutic treatment should 
be changed to minimize the risk of progression and of mortality 59. 
Failure is a frequent event: for imatinib, the most common first-line treatment, 
primary failure is assessed in around 40% of patients.  
Patients who fail imatinib must switch to second-generation tyrosine kinase 
inhibitors. However, 37 to 52% of patients do not respond neither to these 
treatments 148,149, and 23 to 26% lose the initial MCyR within 2 years 149. 
According to literature data, the most common cause is connected to drug 
resistance; in addition, unacceptable side effects are commonly associated with 
therapeutic failure, as well 150. 
1.7.6. Resistance to treatment 
10 to 20% of newly diagnosed CP-CML patients exhibit primary or acquired 
resistance to frontline TKI therapy, and responses in patients with BP CML are 
usually transient 145,151. 
Resistance to TKIs can occur due to the several mechanisms, which can be either 
Bcr-Abl dependent of independent.   
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Among Bcr-Abl mechanisms, point mutations of the BCR-ABL kinase can be 
detected in around 50% of patients who experience treatment failure or disease 
progression 152-155. These mutations are probably the most clinically relevant 
mechanism for resistance, since they are responsible for changes in the 
conformation of the kinase domain which can interfere with the TKI binding 91. 
These mutations are independent from the transcript and kinase polymorphisms, 
and have been associated with a higher genetic instability and an increased risk in 
progression, due to a loss of response to TKI treatment 156. 
In particular, different mutations can lead to the resistance to different TKIs.  
Using the Sanger sequencing technique, more than 80 different amino acidic 
substitutions have been detected and associated with the development of imatinib 
resistance 152,155. For dasatinib, instead, the mutation which are more frequently 
connected to resistance are the V299L, F317L/V/I/C, T315A, or T315I, whereas 
patients developing resistance to nilotinib are usually detected with the Y253H, 
E255K/V, F359V/C/I, or T315I mutations 154,155. Of note, patients carrying the 
T315I mutation are resistant to imatinib, dasatinib, nilotinib and bosutinib, and the 
only TKI effective for this mutation is ponatinib 157-159.  
Besides point mutation, the amplification of the Bcr-Abl can be involved in TKI 
resistance, as well. The association between Bcr-Abl gene amplification and the 
activity of the BCR-ABL kinase has been reported by different studies 160,161. 
However, the real impact of this mechanism is still under investigation.  
Among Bcr-Abl independent mechanisms, instead, different proteins involved 
in drug efflux and influx could be involved in TKI resistance. Among them, the 
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overexpression of the Pgp efflux transporter has been suggested as a possible 
mechanism, due to the role of the Pgp in the transport of TKIs outside the cell; 
however, up to now this mechanism has not been detected in patients resistant to 
imatinib 162,163. Similarly, the uptake transporter hOCT1 could be involeved in 
imatinib resistance, as well 91.  
In addition, several signalling molecules have been considered as possibly 
implicated in TKIs resistance, including STAT3,11 PP2A30,47 and β-catenin 164-
166. Among them, β-catenin is worth of note, since it resulted to be involved in 
several steps of CML progression and resistance to treatments 164-167. In particular, 
β-catenin results to be stabilized by BCR-ABL kinase 168, and increased 
concentration of nuclear β-Catenin have been found in imatinib-resistant        
patients 166.  
1.7.7. Intolerance to treatment  
Beside development of TKI resistance, occurrence of severe intolerance to the 
treatment represents an important concern in CML management. Severe intolerance 
can in fact invalidate the durability of treatment, while increasing the risk of 
morbidity and mortality 169.  
According to phase III RCTs, 6-11% of imatinib-treated patients discontinued 
the treatment because of adverse events 113,131,170. In particular, according to the 
IRIS RCT the lead to the approval of imatinib 105, the most common adverse events 
reported during imatinib treatment were oedema and nausea (both of which 
involving more than 50% of patients), followed by osteoarticular cramps or pain, 
diarrhoea, dermatologic manifestations, and asthenia.   
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Compared to imatinib, second and third generation TKIs showed some 
variability in term of induction of side effects. In particular, compared to imatinib, 
nilotinib has been associated with higher risk of dermatologic manifestations, 
headache, pancreatitis, and cardiovascular events. On the other hand, dasatinib 
resulted to be associated with a lower risk of oedema, but with an increased risk of 
gastrointestinal toxicity and of pleural effusion 169.  
The reasons sustaining this variability among TKIs risk profiles are still 
debatable. A possible explanation could be based on the inhibition of non-BCR-
ABL kinases (such as FGFR1, FLT3, KIT, PDGFR, or SRC) differently mediated 
by each TKI 105,113,131,170,171. 
Ponatinib instead resulted to be associated with particularly high frequency of 
cardiovascular toxicity, including arterial thrombosis (8 %), myocardial infarction 
(5 %), peripheral arterial occlusive disease (PAOD) (2 %), and cerebrovascular 
events (2 %) 172. Serious arterial thrombotic events and cardiovascular toxicities 
were reported in 5-7% of ponatinib-treated patients enrolled in the EPIC and PACE 
trials, respectively 132. What’s more, results from another RCT showed that around 
50% of patients treated with frontline ponatinib experienced either cardiac or 
vascular events, which lead to the early stop of this trial 133. 
Cardiovascular toxicity, however, is not limited to ponatinib treatment, and still 
represents one of the major concerns during CML treatment, independently from 
the chosen therapy. Cases of QT prolongation have been reported during treatment 
with all TKIs. In particular, nilotinib has been associated with the highest risk of 
cardiac arrhythmias, which led to cases of sudden death during trials and to the 
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subsequent recommendation of close electrocardiogram evaluations before and 
during treatment 109,110.  
A retrospective cohort analysis by Giles et al. 173, further reported a higher 
incidence of PAOD among nilotinib-treated patients compared to imatinib. 
However, in a study conducting adopting a SCORE risk assessment tool from the 
European Society of Cardiology to distinguish the personal cardiovascular risk of 
each patient, no cardiovascular events associated with nilotinib treatment were 
found among low-risk patients 174. The use of risk assessment tools in both RCTs 
and real life treatment could therefore help to identify which group of patients could 
experience the worse adverse events, as well as to estimate the true cardiovascular 
impact of nilotinib on each subset of patients.   
Development of heart failure is considered instead to be quite uncommon for all 
TKIs treatments 97,175-177.   
A possible mechanism responsible for TKI cardiovascular toxicity could be 
connected to the TKI-dependent inhibition of non- BCR-ABL kinases involved in 
the vascular endothelial regulation, such as the VEGF 178,179.  
In addition, nilotinib was reported to be associated with increased levels of 
plasma glucose and with alterations in the lipid profile, which on their turn could 
lead to cardiovascular disorders 112,180.  
Similarly, also dasatinib was found to be associated with increased cholesterol 
levels, comparable to that of nilonib-treated patients and significantly higher than 
those of patients in imatinib 181. 
  
45 
 
In light of this, a careful evaluation of cholesterol, glycated haemoglobin and 
glycaemia levels should be performed before treatment beginning, in order to 
identify subjects at higher risk of developing glycometabolic disorders and to guide 
the choice of the most appropriate TKI. 
Besides cerebrovascular complications, all BCR-ABL TKIs have been 
associated with the occurrence of pleural or pericardial effusions, with dasatinib 
being associated with the highest risk 169. In the DASISION trial, in particular, 20% 
of patients needed to discontinue dasatinib treatment due to occurrence of pleural 
effusion, and 5% of patients were found with pulmonary arterial hypertension, a 
severe pulmonary toxicity 182.  
Data from medical literature have further reported a not-well-established risk of 
secondary malignancies developed following TKIs treatment. In particular, a study 
conducted in 2005 suggested an increased risk of malignancies among imatinib-
treated patients, with the occurrence of prostate cancer being four times higher 
compared to the general population 183. According to a recent population study 
based on The Surveillance, Epidemiology, and End Results (SEER) database, the 
risk of secondary malignancies is the highest in the first year of TKI treatment 184.  
Imatinib, in fact, plays immune-regulatory effects through the inhibition of T-
cells activation and proliferation and through the reduction of primary T-cell 
responses mediated by dendritic cells 185,186. In addition, in vitro studies shew an 
association of imatinib with genetic instability 185-187, which was seen to 
significantly affect the development as well as the progression of many            
cancers 188,189.  
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1.7.8. The gold standard: the stable discontinuation of treatment 
According to the current recommendations of both the National Comprehensive 
Cancer Network (NCCN) and the ELN, TKI treatment for CML patients should be 
continued indefinitely 59,190. 
Despite the great effectiveness of these drugs, however, a life-long treatment 
with TKIs can be associated with an increased risk of the above mentioned side 
effects, deeply compromising patients’ quality of life 191,192. In particular, treatment 
discontinuation may be particularly relevant for fertile women who have achieved 
an optimal response, because TKI treatment is contraindicated during conception 
and pregnancy. In these patients, when the optimal response is stable for at least 2 
years, TKI discontinuation can be considered, after informed consent and with very 
frequent molecular monitoring 58 .  
Therefore, attempts have been made to evaluate whether therapeutic treatment 
can be stably and safely discontinued following the achievement of a deep response.  
Cases of successful discontinuation have been reported in the past year in 
patients with CCyR following IFN treatment 193,194. Later on, several studies have 
been conducted to evaluate the effects of stable imatinib discontinuation 195-197.  
According to these studies, up to 50% of patients who discontinued imatinib 
treatment after having achieved deep responses, maintained MMR in median 
follow-up of 7.5 years 198. The probability of relapsing after the first 6 months of 
discontinuation was estimated at 10% 199. What’s more, relapsing patients could re-
start treatment and re-obtain deep responses with the same TKI 199, therefore 
providing assurances on the safety of treatment discontinuation.  
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Up to now, data on discontinuation of second-generation TKIs are instead poor. 
Preliminary results of a French pilot study showed that around 60% of patients 
discontinuing a second-generation TKI maintained MMR after 12 months 200.  
As for imatinib, cases of relapse following dasatinib discontinuation are more 
frequent within the first 7 months, with re-initiation of treatment allowing to re-gain 
deep molecular responses within 6 months of re-treatment 201.  
The possibility of stable and safe treatment discontinuation represents also an 
important economic challenge. In fact, due to the long-term survival provided by 
current therapeutic options and to the increasing trend in prevalence, life-long 
continuation of therapy currently represents a consistent burden for the National 
Healthcare System (NHS) 202.  
Identifying predictive factors for successful discontinuation of TKI remains a 
key issue. Several independent study correlate longer durations of response, 
especially of deep MR before stopping, with lower rates of relapses 192. In the STIM 
study, imatinib therapy duration and Sokal risk score have been identified as 
independent prognostic factors for molecular relapse after imatinib cessation: in 
particular, patients treated for more than 50 months and at lower risk according to 
the Sokal score, had significantly lower rates of relapse compared to patients treated 
with imatinib for fewer than 50 months or at high risk of progression196.  
So far, data available from literature indicate that all patients who have relapsed 
remain sensitive to TKI re-treatment, therefore providing evidence of the safety of 
treatment discontinuation 192. 
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1.7.9. Regulatory aspects and costs of TKI treatment in Italy  
1.7.9.1.TKIs prescription and delivery 
 
Imatinib (Glivec) was the first BCR-ABL TKI that entered the Italian market, in 
2001. Dasatinib (Sprycel) and nilotinib (Tasigna) became available a few years 
later, in 2006 and 2007, respectively. In 2017, following the expiration of Glivec, 
generic imatinib entered the market, as well.  
In Italy, prescription of all TKIs is limited to haematologist physicians; at time 
of TKI prescription, compilation of a therapeutic plan is compulsory. 
The therapeutic plan is a module, filled by the hospital specialized doctor, that 
since 1994 has been declared necessary by the Italian Agency of Medicines (AIFA) 
and by the Health Ministry for the prescription of some drugs, among which TKIs. 
Therapeutic plans have been introduced for the definition of the reimbursement of 
the considered drugs, as well as for the assurance of the therapeutic appropriateness.  
Data reported in the therapeutic plan include: data of the authorized centre 
prescribing the drug; patient’s personal data; name of the patient’s general 
practitioner; diagnosis of the pathology; drug prescribed, doses, and time of 
administration; duration of therapy. 
Three copies of the therapeutic plan must be completed; one remains within 
patient’s medical records, one is for the patient’s general practitioner, and the last 
one is for the pharmaceutical service of the Local Health Authority (LHA) of 
patient’s residence.  
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Following prescription by the haematologist, TKIs are delivered to patients 
directly by the hospital pharmacy. For second and third generation TKIs, the 
delivery of the drug must be accompanied by the compilation of a specific register 
created by AIFA.  AIFA registers represent a tool introduced in 2005 to assure the 
prescriptive appropriateness, as well as to control the pharmaceutical expenditure.   
Information requested by AIFA register include data of the authorized centre 
prescribing the drug; patient’s personal data; pathology for which the drug is used; 
drug prescribed, doses, and time of administration; line in which the treatment is 
administered; eventual causes of switch to a further therapeutic line.  
1.7.9.2.Costs of TKIs treatment in Italy 
In Italy, pharmacological management of CML in entirely reimbursed by the NHS, 
i.e. patients do not have to pay for these medications.  
Retail prices for a treatment, as reported in the Italian “Informatore del  
Farmaco” 203, are shown in table 1.3. However, real prices at which each hospital 
buys TKIs may vary according to internal tenders with pharmaceutical companies, 
as well to private discounting practices.  
Focusing on drugs approved in first line, costs per day of treatment with imatinib 
(assumed at the dose of 300 mg/die) range from 11.67 euros for the generic imatinib 
to 104.93 euros for the brand Glivec (120 capsules, 100 mg). Costs per day for 
Tasigna and Sprycel are instead of 165.33 and 220.90 euros, respectively.   
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Active 
principle 
Pharmaceutical 
industry 
Dosage 
Originator 
(O) / Generic 
(G) 
Daily 
dose 
Price (€) 
Cost (€) 
per day 
Glivec Imatinib 
mesilato 
Novartis farma spa 120 capsules; 
100 mg 
O 400 mg 3147.80 104.93 
Imanivec Imatinib 
mesilato 
KRKA 
Farmaceutici 
Milano 
120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Accord 
Imatinib 
mesilato 
Accord Healthcare 
Italia 
120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Accord 
Imatinib 
mesilato 
Accord Healthcare 
Italia 
30 tablets; 
400 mg 
G 400 mg 911.04 30.37 
Imatinib 
AHCL 
Imatinib 
mesilato 
Dr Reddy’s 
Laboratories Ltd 
120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Aurobindo 
Imatinib 
mesilato 
Aurobindo Pharma 
Italia 
120 capsules; 
100 mg 
G 400 mg 350.00 11.67 
Imatinib 
DOC 
Imatinib 
mesilato 
DOC generic 120 capsules; 
100 mg 
G 400 mg 300.00 11.67 
Imatinib 
EG 
Imatinib 
mesilato 
EG 120 capsules; 
100 mg 
G 400 mg 300.00 11.67 
Imatinib 
Fresenius 
Kabi 
Imatinib 
mesilato 
Fresenius Kabi 
Italia 
60 tablets; 
100 mg 
G 400 mg 455.52 30.37 
Imatinib 
Mylan 
Imatinib 
mesilato 
Mylan 120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Mylan 
Pharma 
Imatinib 
mesilato 
Mylan 120 capsules; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Ranbaxy 
Imatinib 
mesilato 
Ranbaxy Italia 120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Sandoz 
Imatinib 
mesilato 
Sandoz 120 tablets; 
100 mg 
G 400 mg 944.34 31.45 
Imatinib 
Teva 
Imatinib 
mesilato 
Teva Italia 120 capsules; 
100 mg 
G 400 mg 400.00 13.33 
Tasigna Nilotinib 
cloridrato 
monoidrato 
Novartis farma 112 capsules; 
150 mg 
O 600 mg 4629.36 165.33 
Tasigna Nilotinib 
cloridrato 
monoidrato 
Novartis farma 112 capsules; 
200 mg 
O 600 mg 6172.47 165.35 
Sprycel Dasatinib Bristol-Myers 
Squibb 
30 tables; 
100 mg 
O 100 mg 6626.92 220.90 
Sprycel Dasatinib Bristol-Myers 
Squibb 
30 tables; 
140 mg 
O 140 mg 6626.92 220.90 
Sprycel Dasatinib Bristol-Myers 
Squibb 
60 tables; 50 
mg 
O 100 mg 6626.92 220.90 
Sprycel Dasatinib Bristol-Myers 
Squibb 
30 tables; 80 
mg 
O 80 mg 6626.92 220.90 
Iclusig Ponatinib Incyte Biosciences 
Italy 
60 tables; 15 
mg 
O 15/30 
mg 
8862.55 147.71/ 
295.42 
Iclusig Ponatinib Incyte Biosciences 
Italy 
30 tables; 45 
mg 
O 45 mg 8862.55 295.42 
Bosulif Bosutinib Pfizer 28 tables; 
100 mg 
O 500 mg 1543.12 275.56 
Bosulif Bosutinib Pfizer 28 tables; 
500 mg 
O 500 mg 6172.47 220.44 
Table 1.3: Retail prices for TKI treatments, taken from www.codifa.it 
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1.8. Rational and Aim 
As extensively described in the introduction to this thesis, TKIs have deeply 
revolutionized the prognosis of CML, proving to be very effective and accounting 
for survivals comparable to those of the general population.  
As CML has progressively switched from a fatal to a “chronic” pathology, 
standards for the management of CML have moved from short-term survival to 
long-term outcomes, such as achieving of early deep responses, reducing persistent 
treatment intolerance, and potentially stopping treatment in stable patients 204. 
Data coming from RCTs have therefore progressively become inadequate to 
assess this, due to their relative short times of follow-up compared to the overall 
real-life duration of the pathology 204. 
Besides “temporary” limitations, populations carefully selected for enrolment in 
RCTs appear to be quite different from those found in everyday practice. According 
to a German study, for example, patients enrolled in a CML RCT were in average 
11 years younger than patients excluded from it 205. Such a difference in age appear 
to be crucial in the assessment of clinical outcomes, with significant differences 
being reported in the occurrence of adverse events for older patients compared to 
those enrolled in RCTs 206. 
In light of this,  
“a shift in focus from data provided by RCTs to more longitudinal, patient-centric 
outcomes, such as those addressed in observational studies, may be helpful” 204. 
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This thesis aims therefore to take a picture of the management of CML over a 
decade of real clinical practice in the LHA n.2, Region of Veneto, District of 
Treviso (Italy), addressing long-term outcomes such as treatment switches, TKI 
effectiveness and occurrence of adverse events. 
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2. MATERIALS AND METHODS 
2.1. Consulted administrative databases 
A retrospective cohort study was performed on the population affected by CML and 
followed up at the Department of Haematology of the LHA n.2, Region of Veneto, 
District of Treviso (Italy). 
Data were collected from local administrative databases and included: 
 demographic data on NHS beneficiaries; 
 prescriptions of medicines reimbursed by the NHS and delivered either 
by territorial or hospital pharmacies: 
 therapeutic plans, i.e. specific forms filled in by the physician for the 
prescription and delivery of some drugs, among which TKIs; 
 AIFA national registers, i.e. registries created by the Italian Agency of 
Medicines (AIFA) and filled in at time of drug delivery for the 
monitoring of the use of specific drugs, among which second and third 
generation TKIs: 
 hospital discharge records and emergency room attendances, with 
primary or secondary diagnosis fields coded through ICD9-CM codes;  
 blood laboratory tests with their results. 
Record linkage among databases was performed using the individual patient 
identification code (Regional Health Code-RHC) attributed by the NHS to each 
beneficiary.  
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In accordance with the Italian rules on privacy, the original RHC was replaced 
by an anonymous unique alphanumeric identifier.  
Besides administrative databases, data coming from the physicians’ patient 
record (PPR) were available as well. The PPR is an internal registry completed by 
the haematologist at time of each physician visit, and contains information on 
patient’s anamnesis, CML phase at entry, symptoms at diagnosis, risk scores of 
CML progression, type of BCR-ABL transcript, eventual presence of ACAs, 
therapeutic treatments, treatment switches and causes, adverse effects (AEs) of 
treatments, as well as results of haematochemical, cytogenetic and molecular tests.  
2.2. Identification of the cohort: inclusion and exclusion criteria 
The cohort of patients affected by CML was identified in the period from January 
1st 2005 to June 30th 2015. 
Patients matching at least one of the following criteria were included in the 
study: 
 hold of a therapeutic plan for a TKI drug, with CML as indication for 
use; 
 registration in the AIFA registers for the monitoring of use of second or 
third generation TKIs, with CML as indication for use; 
 hospitalization(s) with a diagnosis of CML (ICD9-CM code 205.1) in 
primary or secondary diagnosis field. 
According to these inclusion criteria, 163 patients were identified as affected by 
CML (figure 2.1).  
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Of them, all patients with no available information on their therapeutic treatment 
(n=31) were excluded: these patients had been occasionally hospitalized for CML 
in the Hospital of Treviso, but were then followed up in other Italian hospitals. 
Similarly, patients that were diagnosed with CML before TKI availability and that 
prosecuted non-TKIs treatments during the whole study period (n=13) were 
excluded from the study.  
The final examined cohort was therefore composed of 119 patients affected by 
CML. For 103 of them, PPR was accessible, as well.  
For each patient, the real date of diagnosis was captured from his/her PPR. If 
unavailable, the date of diagnosis was estimated as proxy, considering the first date 
among first TKI prescription or the first hospitalization with a diagnosis of CML.  
From the date of diagnosis, all patients accumulated person-time until the 
occurrence of the first of i) HSCT transplantation, ii) death, or iii) end of data 
availability (December 31st 2015). The first date among these events was 
considered as exit date. 
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Figure 2.1: Study design and examined outcomes 
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2.3. Characterization of the cohort 
All patients were characterized based on demographic information, i.e. gender and 
age at diagnosis. When available, patients were characterized also by further 
information taken from PPR, i.e. i) CML phase at onset, ii) Sokal-Hasford-EUTOS 
risk scores, iii) symptoms reported at time of diagnosis, iv) BCR-ABL transcript 
type, and v) presence of ACAs at time of CML diagnosis.  
Besides the above mentions characteristics, the presence of other comorbidities 
at baseline was evaluated as well. Data concerning comorbidities were captured 
from either: 
 anamnestic information reported in the PPR; 
 hospitalizations occurred at any time before CML diagnosis, considering 
ICD-9 CM codes reported in table 2.1 in either primary or secondary 
diagnosis fields; 
 therapies used at time of diagnosis, captured from the databases of 
territorial and hospital drug deliveries, considering ATC codes reported 
in table 2.1. 
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Comorbidities ICD9-CM codes  ATC codes  
Autoimmune pathologies 2420* or 2452* or 555* or 
556* or 696* or 710* or 714* 
or 720* 
L04* 
Cardiovascular pathologies 402*-404* or 410*- 
414*or 427*-438* or 7850 
C01* 
Diabetes 250* A10* 
Disorders of thyroid gland 240* - 246* H03* 
Dyslipidaemia 272* C10* 
Gastrointestinal diseases 530* - 535* - 
Hypertension 401* C02* or C03* or C07* or 
C08* or C09* 
Mental disorders 290*-319* N05* or N06* 
Neurologic pathologies 330*-337* or 340*-345* N03* or N04* 
Obesity 278* A08* 
Osteoarticular pathologies 715* or 733* M05* 
Previous cancer 104*-208* - 
Renal diseases 584* or 585* - 
Chronic respiratory 
pathologies 
491* or 492* or 493* or 
496 
R03* 
Table 2.1: ICD9-CM and ATC codes considered for the evaluation of comorbidities 
 
2.4. Evaluation of therapeutic pattern 
The pharmacological treatment of CML was evaluated starting from the date of 
diagnosis. Data on active drug, length of treatment, therapeutic switches and reason 
for switch (where available), were collected from both PPR and administrative 
databases of territorial and hospital drug deliveries. Of note, therapies were 
evaluated up to the third line of treatment, i.e. after the occurrence of two 
therapeutic switches; treatments prescribed after the third line were not included in 
the analysis. 
In addition, variations in drug dosage and temporary interruption of treatment 
(for up to 2 consequent physician visits) without changes of the drug were not taken 
into account. These patients were not considered as switchers, and were therefore 
counted in the same therapeutic line.  
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Baseline characteristics were compared between CP CML patients prescribed 
with first vs second generation TKIs, to evaluate whether these factors influenced 
treatment choice as well as to consider their impact on responses to treatment.   
2.5. Assessment of treatment effectiveness  
The effectiveness of therapeutic treatments was evaluated based on the achievement 
of:  
 CHR, defined as platelet count <450x109L and white blood cells count 
<10x109L; 
 CCyR, defined as the non-detectability of the Ph chromosome through 
cytogenetic FISH analysis; 
 MMR, defined as BCR-ABL transcript levels <0,10 IS detected through 
RQ-PCR; 
 CMR, defined as the non-detectability of the BCR-ABL transcript 
through RQ-PCR. 
The definitions of the above mentioned responses were based on the ELN 
guidelines 59. 
Results of blood tests were captured from both PPR and the administrative 
database. Instead, results of cytogenetic and molecular analysis were captured only 
from PPR.  
Responses were evaluated both in the overall period, i.e. independently from the 
time of their achievement, and at specific time milestones, i.e. 3 - 6 - 9 -12 and 24 
months after treatment beginning.  
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Effectiveness of TKIs was assessed overall. In addition, a comparison of the 
effectiveness of the different TKIs as frontline treatment for CP patients was 
performed. Time of response achievement was calculated from the first date of TKI 
prescription to the date of achievement of the considered response. An intention-to-
treat approach was used, i.e. achievement of responses was arbitrarily attributed to 
the frontline treatment used, although a therapeutic switch might have occurred 
later. The choice of using this approach rather than a per-protocol analysis was 
driven by the difficulty of estimating the contribution of previous treatments on the 
achievement of responses.  
2.6. Evaluation of the development of additional chromosomal alterations 
Development of ACAs was evaluated according to CML phase at entry. In addition, 
the occurrence and the time to development of ACAs was compared among 
different frontline TKIs. For this comparison, an intention-to-treat approach was 
used, i.e. occurrence of ACAs was attributed to the frontline TKI, although a 
therapeutic switch might had occurred and a different TKI was currently used at 
time of ACAs development.      
2.7. Evaluation of adverse effects  
Occurrence of AEs was evaluated at any time following treatment beginning, based 
on adverse manifestations reported in the PPR, hospitalizations and emergency 
room attendances. 
AEs were evaluated in the overall cohort of patients, independently from CML 
phase and therapeutic treatment. Furthermore, for patients in CP, occurrence of AEs 
during frontline treatment was compared among different TKIs.   
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2.8. Statistical analysis 
Descriptive statistic was used to summarize demographics and baseline 
characteristics. 
Continuous variables were reported as median values and range (min-max 
values), and were compared using a Kruskal-Wallis test. Percentages were 
compared using Fisher exact test.  
A Cox univariate regression model was fitted, with patients accumulating time 
from treatment beginning to the date of achievement of the considered response 
(either CHR, CCyR, MMR or CMR). Achievement of responses among different 
TKIs was compared using a Kaplan Meier model.  
Missing data were randomly distributed; cause for missing data was the loss of 
the records of some laboratory and clinical examinations during the study period. 
In each analysis, subjects with no available data for the considered variable were 
excluded. In the analysis of treatment effectiveness, missing data at specific time 
milestones were imputed equal to those of the previous measure.  
Statistical analysis was performed using the software STATA version 14. 
Statistical significance was considered with p-values <0.05. 
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3. RESULTS 
3.1. Incidence and prevalence of CML  
A total cohort of 119 patients affected by CML was identified from January 1st 
2005 to June 30th 2015. For 93 of these patients, first diagnosis of CML had actually 
occurred during this period, with a median incidence of 9 cases/year [range: 2 cases 
in 2007 -13 cases in 2010]. On the other hand, 26 patients were diagnosed between 
1997 and 2004 (figure 3.1).  
Of note, also people resident outside the District of Treviso but followed up in 
the hospital of Treviso were enrolled in this study; therefore, these results do not 
allow to calculate an incidence and prevalence rate of CML in the considered 
District. 
Figure 3.1: prevalence to CML over years 
 
Overall, the median observational time [range] for these patients was 2190.5 
days [85 – 6848]. 21 of these patients exited the study because of death, after a 
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median time of 2164 days [85 – 6186]. The median rate of mortality was of 2 
deaths/year [0 – 7]. 3 patients exited the study because of HSCT, after a median 
time of 350 ± 69 years. All other patients were follow-up until December 31st 2015. 
 
3.2. Baseline characteristics of the cohort 
3.2.1. General patients-related characteristics  
The baseline characteristics of the cohort are described in table 3.1. Information on 
CML phase at entry was available for 103 out of 119 patients. 97 patients were 
diagnosed in CP, 1 in AP, and 5 in BC.  
Considering sex, 63 patients were men and 56 were women, with a men : women 
ratio of 1.13. Sex had equal distribution among CML phases at diagnosis. 
The mean age ± SE at diagnosis was of 60.38 ± 1.31 years, with more than 50% 
of patients being 55 or older at diagnosis. No significant variation in mean age was 
found among patients diagnosed in CP, AP or BC.   
Considering CML-related information, the majority of patients were considered 
at low risk of progression. 11 out of 61 patients with Sokal score, 3 out of 24 
subjects with measurement of Hasford score, and 5 out of 28 subjects with EUTOS 
score, were classified at “high risk”.  
 
  
* 
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n.c.= not calculable 
Table 3.1: Baseline patient’s-related characteristics, overall and stratified according to CML phase 
at entry 
 
3.2.2. CML-related characteristics 
General CML-related characteristics are reported in table 3.2.  
Information on the type of BCR-ABL transcript and on the presence of ACA at 
diagnosis was available for 77 out of 119 patients.  
The e14a2 or the e13a2 transcripts, coming from the major BCR breakpoint, 
were the most common (41 and 30 patients, respectively).  2 patients carried instead 
both e14a2 and e13a2 transcripts. The less common e19a2 transcript, coming from 
Characteristics n 
Chronic 
phase 
(n) 
Accelerated 
phase 
(n) 
Blast crisis 
(n) 
p-
value 
Phase at entry 103 97 1  5  
Sex 
N obs 119 97 1 5  
Men 63 52 1 3 1.00 
Women 56 45 0 2  
Age at diagnosis 
N obs 119 97 1 5  
Median age [range] 62 [25-95] 61 [25-95] 79 61 [40-75] 0.31 
<35 years 7 6 0 0 0.84 
35-54 years 34 29 0 2  
55-74 years 61 50 0 2  
>74 years 17 12 1 1  
Sokal score 
N obs 61 61 0 0  
Low 31 31 - - n.c. 
Intermediate 19 19 - -  
High 11 11 - -  
Hasford score 
N obs 24 24 0 0  
Low 15 15 - - n.c. 
Intermediate 6 6 - -  
High 3 3 - -  
EUTOS score 
N obs 28 28 0 0  
Low 23 23 - - n.c. 
High 5 5 - -  
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the minor BCR breakpoint, was detected in another 2 patients. The rare e6a2 and 
e1a2 transcripts were present instead in 1 patient each.  
Of note, the type of BCR-ABL transcript resulted to significantly correlate with 
CML phase at entry (p =0.01). In particular, the majority of patients diagnosed in 
CP carried either the e14a2 or e13a2 transcripts; this latter transcript was found also 
in the patient diagnosed in AP. On the other hand, patients carrying either the e6a2 
or the e1a2 transcript were all diagnosed in BC, with these two transcripts 
accounting for 2 out 3 of cases of BC with information on BCR-ABL transcript. 
Considering other chromosomal abnormalities, 12 out of 77 patients presented 
ACAs at diagnosis; 11 of them were diagnosed in CP, whereas 1 patient was in BC. 
 
Table 3.2: Baseline CML-related characteristics, overall and stratified according to CML phase at 
entry 
  
Characteristics n 
Chronic 
phase 
(n) 
Accelerated 
phase 
(n) 
Blast 
crisis 
n 
p-
value 
BCR-ABL transcript 
N obs 77 73  1  3   
e14a2 41 40  0  1  0.01 
e13a2 30 29  1  0   
e14a2/e13a2 2 2  0 0  - 
e19a2 2 2  0  0 - 
e6a2 1 0  0  1  - 
e1a2 1 0  0  1  - 
Presence of ACAs 
Positive for ACA 12 11 0 1 0.14 
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3.2.3. Evaluation of symptoms at diagnosis 
Symptoms diagnosis were available for the 103 patients with PPR (figure 3.2). 
60 of them reported no symptom at diagnosis, with leucocytosis and consequent 
research for Ph chromosome being detected by chance during routinely laboratory 
tests.  
Even when present, symptoms resulted to be broadly unspecific. In particular, 
weight loss, asthenia and fever were the most common (12, 10 and 7 patients).   
In addition, 23 out of 103 patients were found with hepatosplenomegaly at the 
first physician visit. 
 
Figure 3.2.: Evaluation of symptoms at diagnosis (n out of 103 patients) 
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3.2.4. Assessment of comorbidities at baseline 
Information on additional comorbidities at baseline was available for all 119 
patients (figure 3.3).  
Cerebro-cardiovascular pathologies were the most common comorbidity (n=63), 
followed by arterial hypertension (n=59), and chronic respiratory pathologies 
(n=42). 
Furthermore, 26 patients had history of other malignancies. In particular, breast 
cancer represented 23.08% of cases of previous cancers (n=6 out of 26), followed 
by hematologic neoplasia and colorectal cancers (n=4, 15.38% each). Other forms 
of previous malignancies included lung and bladder cancer (n=3 cases each), brain, 
cutaneous, prostate and uterine cancer (n=2 cases each), and laryngeal, kidney, 
stomach, and thyroid cancer (n=1 case each). 
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Figure 3.3: Evaluation of comorbidities at diagnosis 
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3.3. Evaluation of therapeutic pattern 
Therapeutic treatment was evaluated separately according to CML phase at entry. 
Out of the 97 patients diagnosed in CP, 73 started a first line therapy with 
imatinib, whereas 8 were prescribed with nilotinib. First-line non-TKIs treatments 
with HU or IFN were found in 9 and 7 patients, respectively (figure 3.4.a, table 
3.3). 
Median length of treatment was comparable in the imatinib vs nilotinib groups 
(1663 [13-4106] vs 1313 [281-1805], respectively; p=0.40) (table 3.3).  
However, the percentage of switches resulted to be different in the two groups: 
among imatinib-treated patients, therapeutic switches to a second line drug occurred 
in 28 out of 73 patients; on the other hand, all patients treated with frontline nilotinib 
prosecuted this therapy without switches. Switches from imatinib were mainly 
related to intolerance (19 out of 28 cases), but 8 cases were attributable to resistance. 
Patients interrupting imatinib mainly switched to a second generation TKI (15 
to dasatinib and 12 to nilotinib). Of note, one patient interrupted imatinib and 
remained off-therapy for 593 days, because of severe intolerance (figure 3.5.a).   
Considering second line TKI therapies, imatinib, dasatinib and nilotinib were 
used in 14, 15 and 12 patients, respectively. The median duration of treatment for 
imatinib resulted to be significantly longer compared to that of dasatinib or nilotinib 
(4505 [193 – 5520], 1127 [349 – 2183] and 760 [28 – 2450] days for 
imatinib, nilotinib, and dasatinib, respectively; p-value=0.01). However, the three 
 70 
 
treatments resulted to be comparable in term of switches (5 patients in each group; 
p-value=0.92) (table 3.3). 
Patients switching from a second line treatment mainly moved to a different 
second generation TKI. Of note, 2 patients moved to ponatinib, a third generation 
TKI. In addition, 5 patients discontinued therapy without starting a new treatment; 
of them, 3 patients interrupted the treatment because of severe toxicity, whereas 2 
patients discontinued the therapy following the achievement of a stable complete 
response after 5291 and 6805 days, respectively. 
One patient was diagnosed in AP. This patient was treated with imatinib in first 
line for 2247 days, with no switches to other drugs (data not shown).   
Among the 5 patients diagnosed in BC, dasatinib resulted to be the most common 
first line treatment (3 patients), whereas imatinib and dasatinib were used in one 
patient each (figure 3.4.b).   The patient initially treated with imatinib switched to 
dasatinib after 9 days, because of treatment intolerance. On the other hand, the 
patient treated with frontline nilotinib stably continued this treatment for 336 days 
(table 3.3). Among the 3 patients treated with dasatinib, instead, 2 subjects needed 
to switch to cytarabine (ARA-C), i.e. a pre-HSCT treatment, either in second or in 
third line.  
 
 
 
 
 71 
 
 
 
 
Figure 3.4: Evaluation of the therapeutic pattern for patients diagnosed a) in chronic phase or 
b) in blast crisis. 
*1 patients off-therapy after 1st line treatment due to intolerance. 
 ** 5 patients off-therapy after 2nd line treatment: 3 patients due to extra-haematological toxicity; 
2 patients due to achievement of stable complete response.  
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n.c.= not calculable 
*Median value [min-max] 
Table 3.3: Comparison of length of treatment and occurrence of switches among the different TKI 
therapies in first or second line, stratified according to patients’ phase at entry 
 
 
Comparisons of baseline characteristics of CP CML patients prescribed with first 
vs second generation TKIs as frontline treatment are reported in table 3.4. Imatinib 
and nilotinib groups resulted to be comparable in terms of all considered 
characteristics.  
Treatment 
line 
Phase at 
diagnosis 
Examined 
outcome 
Imatinib 
(N: Tot) 
Nilotinib 
(N:Tot) 
Dasatinib 
(N:Tot) 
p-
value 
First line 
Chronic 
phase 
Length of 
therapy * 
1663 
[13-4106] 
1312.5 [281 – 
1805] 
 0.40 
Time to switch* 
533 
[13 – 4010] 
-  n.c. 
Occurrence of 
Switch 
28:73 0:8 - n.c. 
Cause of switch     
Intolerance 19:28 - - n.c. 
Resistance 8:28 - - - 
Unknown  1:28 - - - 
Second line 
Length of 
therapy * 
4505 
[193 – 5520] 
1127 
[349 – 2183] 
760 
[28 – 2450] 
0.01 
Time to switch* 
3835 
[193 – 4704] 
529 
[349 – 1331] 
917 
[760 – 1595] 
0.14 
Occurrence of 
Switch 
5:14 5:12 5:15 0.92 
Cause of switch     
Intolerance 1:5 1:5 3:5 0.74 
Resistance 1:5 3:5 2:5  
Unknown  3:5 1:5 -  
First line 
Blast 
crisis 
Length  of 
therapy * 
9 336 
160 
[42 – 185] 
0.20 
Time to switch* 9 - 
113.5 
[42 – 185] 
0.22 
Switch 
occurrence 
1:1 0:1 2:3 1.00 
Cause of switch     
Intolerance 1:1 - 0:2 n.c. 
Resistance - - 1:2 - 
Unknown  - - 1:2 - 
 73 
 
n.c.= not calculable 
Table 3.4: Comparison of baseline characteristics among CP CML patients treated with first vs 
second generation TKIs as frontline treatment 
  
Characteristics 
Frontline 
imatinib 
N (%) 
Frontline 
nilotinib 
N (%) 
p-
value 
Tot patients 73 8  
Gender    
Men 38 (52.05) 5 (62.50) 0.72 
Women 35 (47.95) 3 (37.50)  
Age at diagnosis    
Median age [range] 62 [25-87] 60 [39-69] 0.28 
Risk scores of progression 
Sokal score (tot) 49 6  
Low 26 (53.06) 2 (33.33) 0.46 
Intermediate 15 (30.61) 2 (33.33)  
High 8 (16.33) 2 (33.33)  
Hasford score (tot) 20 2  
Low 13:20 1 (50.00) 0.30 
Intermediate 5:20 0 (0.00)  
High 2:20 1 (50.00)  
EUTOS score (tot) 23 1  
Low 21:23 0 (0.00) n.c. 
High 2:23 1 (100.00)  
Genetic characteristics 
Type of BCR-ABL transcript (tot) 57 6  
e14a2 30 (52.63) 3 (50.00) 1.00 
e13a2 23 (40.35) 3 (50.00)  
e14a2/e13a2 2 (3.51) 0 (0.00)  
e19a2 2 (3.51) 0 (0.00)  
Presence of ACAs (tot) 57 6  
Yes 9 (15.79) 1 (16.67) 0.98 
No 48 (84.21) 5 (83.33)  
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3.4. Evaluation of treatment effectiveness 
3.4.1. Achievement of complete and major responses 
The effectiveness of CML treatments was initially evaluated overall, considering 
the time and the proportion of patients achieving CHR, CCyR, MMR and CMR 
independently from therapy and CML phase (figure 3.5).  
Considering hematologic responses, the majority of patients already reached 
CHR within the first 3 months from treatment beginning (n=87 out of 95 patients; 
92%). Percentages of CHR achievement continued growing over time, with 115 out 
of 116 patients (99%) reaching CHR at any time following treatment beginning.  
Similarly, CCyR was reached in 91% of patients (n=89 out of 97 patients), with 
more than 50% of patients achieving it within the first 6 months from treatment 
beginning (n=39 out of 67 subjects, 58%). 
On the other hand, achievement of MMR and CMR resulted to more difficult, 
especially at early time milestones. In fact, only 2 out of 49 patients (4%) reached 
MMR and CMR within the first 3 months from treatment beginning, and less than 
50% of patients reached MMR in the first year of treatment. Overall, however, 85% 
of patients reached MMR (86 out of 101 patients), with 59% of subjects reaching 
also CMR (60 out of 101).  
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Figure 3.5: Evaluation of the proportion of responses, overall and at fixed time milestones 
 
4% 
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Beside this overall analysis, achievement of responses was analysed separately 
according to frontline TKI treatment; for this analysis, only patients diagnosed in 
CP and treated with TKIs in first line were included.  
Nilotinib accounted for higher rate of CHR compared to imatinib (figure 3.6); 
in fact, all eight patients treated with nilotinib reached CHR within the first 3 
months following the start of treatment. On the other hand, only 61 out of 70 
patients treated with frontline imatinib reached CHR in the first 3 months, and a 
further seven later.  
Similarly, nilotinib displayed higher effectiveness measured by CCyR and MMR 
(figure 3.7 and 3.8). In fact, all patients treated with nilotinib reached both CCyR 
and MMR within 24 months from treatment initiation (7 out of 7 and 8 out of 8 
patients where this outcome was recorded).  Only 65 out of 69 imatinib-treated 
patients reached CCyR at any time from imatinib treatment beginning, and only 51 
out of 68 patients reached MMR. 
With regard to CMR (figure 3.9), imatinib had higher rates of response than 
nilotinib. 16 out of 68 imatinib-treated patients reached CMR within 24 months 
from treatment initiation, compared to only 1 out of 8 nilotinib-treated patients. 
Overall, 4 out of 8 patients treated with frontline nilotinib eventually achieved 
CMR, compared to 43 out of 68 imatinib-treated subjects.  
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Figure 3.6:  Achievement of CHR among CP patients treated with frontline imatinib vs nilotinib  
 
Figure 3.7:  Achievement of CCyR among CP patients treated with frontline imatinib vs nilotinib  
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Figure 3.8:  Achievement of MMR among CP patients treated with frontline imatinib vs nilotinib 
 
 
Figure 3.9:  Achievement of CMR among CP patients treated with frontline imatinib vs nilotinib  
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3.4.2. Evaluation of the development of ACAs 
Beside achievement of responses, development of ACAs in patients free from ACA 
at diagnosis was evaluated.  
Overall, 10 out of 88 patients developed ACAs at any time following CML 
diagnosis. Occurrence of ACAs significantly differed according to CML phase (p 
<0.05). In fact, ACAs were more frequent among patients in AP (1 out of 1 patient) 
and in BC (1 out of 4 patients); among patients diagnosed in CP, instead, 8 out of 
75 subjects developed ACAs (figure 3.10).  
 
 
Figure 3.10: Assessment of the development of ACAs in patients with no ACA at diagnosis, 
overall and stratified according to CML phase at entry 
 
The possible correlation between the development of ACAs and the type of 
frontline TKI treatment was evaluated (table 3.5). Among patients treated with 
imatinib in frontline, 5 out of 65 subjects where this outcome was recorded 
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developed ACAs, after a median time of 1640 days [168 – 2801]. Among nilotinib 
and dasatinib-treated patients, 2 out of 6 and 1 out of 3 patients developed ACAs, 
after a median time of 110 [103 – 117] days and 158 days, respectively. 
 
Table 3.5: Occurrence of ACAs according to the different frontline TKIs treatments, overall and 
stratified according to CML phase at entry 
 
  
 Frontline 
imatinib 
N:Tot  
Frontline 
nilotinib 
N:Tot 
Frontline 
dasatinib 
N:Tot 
p-value 
Occurrence of 
ACAs 
5:65 2:6  1:3  0.11 
Median time of 
ACA development 
[min-max] 
1640 [168 – 2801] 110 [103 – 117] 158 0.07 
 81 
 
3.4.3. Evaluation of the adverse effects 
AEs occurred after treatment initiation are reported in figure 3.11. 
Osteoarticular pain and dermatologic manifestations were the most common 
AEs, occurring in 73 and 71 out of 119 subjects, respectively. Other AEs involving 
a significant number of patients included asthenia (n=48), alterations of cardiac 
rhythm (n=35), diarrhoea (n=32), epigastric pain, fever and virus reactivation (n=30 
each).  
Focusing on the most serious AEs, 20 patients were found with heart failure, 14 
with pleural effusion, 7 with stroke or ischemic diseases, 4 subjects with acute 
myocardial infarction, 2 with pericarditis, one patient had an aneurism and another 
patient had subarachnoid haemorrhage. 14 patients developed benign or malignant 
neoformations; of them, 3 subjects had colon cancer and, 2 women developed 
mammary nodules, 2 had thyroid adenoma, 2 had gastric cancer, 1 developed 
prostate cancer, 1 developed basocellular carcinoma,1 had intestinal adenoma, 1 
had uterine cancer, and 1 had a pulmonary nodule.   
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Figure 3.11: Occurrence of adverse effects following CML treatment beginning 
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To evaluate whether AEs differed among TKIs, occurrence of AEs during 
frontline CP-CML treatment was compared in imatinib vs nilotinib groups.  
Osteoarticular pain resulted to be the most common AE (table 3.6), significantly 
more frequent among imatinib-treated patients (50 out of 72 imatinib-treated vs 2 
out of 8 nilotinib-treated patients, p=0.02).  Occurrence of all other AEs were 
similar between imatinib and nilotinib.  
Of note, four patients developed other malignancies: one colon cancer, one 
gastric cancer, one prostate cancer, and another uterine cancer.  
 
 
Table 3.6: Evaluation of the most common adverse events occurring during first line TKI 
treatment in CP patients 
 
  
Adverse effects (AEs) 
Imatinib 
n=73 (%) 
Nilotinib 
n=8 (%) 
p-value 
Most frequent AEs 
Osteoarticular pain 50 (68.49) 2 (25.00) 0.02 
Dermatologic manifestations 49 (67.12) 3 (37.50) 0.13 
Asthenia 29 (39.73) 2 (25.00) 0.70 
Diarrhoea 21 (28.77) 2 (25.00) 1.00 
Epigastric pain 19 (26.03) 2 (25.00) 1.00 
Fever 12 (16.44) 1 (12.50) 1.00 
Virus reactivation 12 (16.44) 1 (12.50) 1.00 
Alterations of cardiac rhythm 3 (4.11) 0 (0.00) n.c. 
Most serious AEs 
Stroke/Ischemic diseases 4 (5.48) 0 (0.00) n.c. 
Malignancies 4 (5.48) 0 (0.00) n.c. 
Pleural effusion 2 (2.74) 1 (12.50) 0.27 
Heart failure 2 (2.74) 1 (12.50) 0.27 
Acute myocardial infarction 1 (1.37) 0 (0.00) n.c. 
Aneurism 1 (1.37) 0 (0.00) n.c. 
Pericarditis 0 (0.00) 1 (12.50) n.c. 
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4. DISCUSSION 
This observational study considered the long-term management of CML with TKIs 
in an Italian real world setting.  
The examined cohort, although very limited in size, was typical of patients seen 
in the real world, in term of both sex and age.  
A slightly higher prevalence was found among men compared to women, 
confirming epidemiological literature 5,207.  
The median age at diagnosis was of 61 years, i.e. 14-15 years older compared to 
that of patients enrolled in the nilotinib vs imatinib ENESTnd RCT, and 13-16 years 
older than that of the dasatinib vs imatinib DASISION RCT 112,208. Furthermore, 
the present population included also patients aged 80 or more at time of CML onset, 
who are usually excluded from RCTs and whose management can be particularly 
critical.  The discrepancy in term of age between real-life and RCTs populations 
has been discussed 204,205, and how such RCTs might be proof predictors of response 
in real world populations has been highlighted  204,206,209. 
Most patients in the examined cohort were diagnosed in CP, in line with 
literature data reporting that around 90% of CML cases are detected during CP 3,5. 
Diagnosis of CML in the examined cohort resulted to be mostly fortuitous, with the 
majority of patients being diagnosed by chance. Even when present, symptoms 
resulted to be extremely unspecific, with weight loss, asthenia and fever being the 
most frequently reported. 
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CML phase at entry resulted to be significantly correlated to the type of BCR-
ABL transcript. In accordance with literature 40, the e14a2 and e13a2 transcripts 
resulted to be the most common, especially among CP patients. Unexpectedly, 
within this small cohort of patients, we reported the presence of the rare e6a2 and 
e1a2 transcripts. Of note, both transcripts were found in BC patients, thereby 
confirming the well-known higher aggressiveness associated with these 
transcripts77,210,211.  
Furthermore, ACAs at diagnosis were found in 12 patients, with no significant 
difference among CML phases. CP-patients carrying ACAs or uncommon BCR-
ABL transcripts were classified at high risk of CML progression. Among ACAs-
free patients, most were considered at low risk of progression, independently from 
the risk score used. Of note, the Sokal score, although developed before TKI advent, 
was the most frequently reported in PPR, confirming how this score is still routinely 
used in clinical practice and is still considered an extremely predictive tool for 
treatment response and patients’ survival 212.   
Although being mostly identified as low-risk patients, the majority of patients 
resulted to be clinically compromised by other comorbidities. In particular, cerebro-
cardiovascular pathologies occurred in more than half of the cohort, and one out of 
five subjects had history of other malignancies. Of note, patients with severe or 
uncontrolled cardiovascular diseases were excluded from both the ENEST, 
ENESTnd and DASISION trials 213-215 and little is known on the best management 
of CML for patients with previous malignancies. 
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In light of this, this study provides important information on the pharmacological 
management of CML in the real clinical practice.  
Our results clearly show a central role of imatinib as first line treatment for CP 
patients, compared to a marginal number of patients prescribed with second 
generation TKIs.  Baseline patients’ and CML related characteristics were 
comparable among CP-CML subjects treated with frontline imatinib vs nilotinib, 
indicating that the choice of frontline treatment was not influenced by these factors. 
Of note, nilotinib was the only second-generation TKI prescribed as first line for 
CP CML, although the indications for its use are comparable to those of dasatinib, 
and there are no specific recommendations on the choice between the two molecules 
59. Dominance of nilotinib could be motivated by its lower cost per day of treatment 
compared to dasatinib (165.33 vs 220.90 euros per day); however, considering that 
real prices at which hospitals buy these drugs might vary according to internal 
private tenders with pharmaceutical companies, this hypothesis cannot be validated 
in practice.  
This pattern of choice of first line treatments for CP patients is adherent to 
international recommendations, that recommend second-generation TKIs in 
patients diagnosed in AP or BC, while leaving to physicians the choice between 
first and second generation TKIs in low-risk CP patients 59.  
Despite the discrepancy in term of patients’ baseline characteristics between this 
study and RCTs, our analysis of the comparative effectiveness of TKIs confirms 
data from RCTs 112,113, highlighting higher rates of early and overall achievement 
of CHR, CCyR and MMR among patients treated with first line nilotinib compared 
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to imatinib. However, unexpectedly, rates of CMR were higher in the imatinib 
group. Although measured baseline characteristics were comparable in imatinib and 
nilotinib groups, these finding may suggest a possible selective use of nilotinib as 
first line in more clinically complex patients. 
2 out of 97 CP-CML patients stably discontinued TKI therapy following the 
achievement of a stable response with imatinib treatment. No case of treatment 
discontinuation and subsequent relapse was reported. This result suggests that to 
date long-term management of CML in clinical practice is mainly based on stable 
prosecution of TKI treatment, in accordance with ELN recommendations 59. 
Although still experimental, stable treatment discontinuation is gaining increasing 
attention in clinical practice, given its crucial impact on patients’ quality of life, 
reduction of adverse effects, as well as on the economic burden of the pathology 
for the NHS 192. Moreover, our study finds a difference in the occurrence of 
therapeutic switches between these two TKIs. In fact, we found no switches in 
patients treated with frontline nilotinib, compared to 28 out of 73 imatinib-treated 
patients who switched to a second-line treatment. This result must be taken 
carefully, given the very small and unbalanced number of patients in the imatinib 
vs nilotinib group, and the different availability of the two TKIs over the observed 
period (imatinib was available in the whole period, whereas nilotinib entered the 
Italian market in 2007). Nevertheless, two recent National and International 
observational studies by Castagnetti et al. and Machado-Alba et al. 216,217 found 
similar results, reporting significantly higher proportion of switches in patients 
treated with imatinib compared to second-generation TKIs, mainly because of 
resistance. 
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On the other hand, in our study, most switches from imatinib were due to severe 
treatment intolerance.  
In fact, our results clearly highlight as AEs remain a critical concern during CML 
management. 61% of examined patients suffered osteoarticular pain following 
CML treatment beginning, with a significantly higher frequency among imatinib-
treated subjects. The association of imatinib with muscle cramps is well known in 
literature 10; this AE, although not serious, can deeply compromise a patient’s 
quality of life, leading to poor compliance to treatment and to need of treatment 
changes. Other frequent AEs included dermatological manifestations, asthenia, 
diarrhea and epigastric pain.  
This study claims the necessity of monitoring of patient’s overall clinical 
condition and of developing a strategy to manage AEs. From this perspective, also 
the ELN recently published recommendations for the management and avoidance 
of AEs of treatment in CML 218. According to them, efforts should be made to 
predict and manage AEs without reducing or interrupting CML treatment. 
Particular attention must be given to comorbidities and drug interactions, and to 
new events unrelated to TKIs that are inevitable during such a long-lasting 
treatment 218. In addition, wider studies on the development of secondary 
malignancies following CML treatment are needed.   
This study has limitations. First, the cohort was small, and confined to one Italian 
district. Evaluation of demographic and disease-related characteristics revealed that 
this cohort was representative of CML population, as described in National as well 
as International literature 5,206,207. Nevertheless, the limited size of this study 
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compromises the generalizability of these results. Second, there was disproportion 
in size between imatinib and nilotinib groups. Third, despite baseline characteristic 
were comparable among CP patients treated with frontline imatinib and nilotinib, 
unmeasured confounding by indication could be present, i.e. nilotinib could have 
been mainly likely in patients with clinical characteristics different from imatinib-
treated subjects. Fourth, this study covers a prolonged period (2005-2015), and 
aspects related to treatment might have changed over this time: in particular, while 
imatinib was available during all this period, nilotinib entered the Italian market 
only in 2007. Fifth, an intention-to-treat approach was used in the analysis of 
treatment effectiveness and ACAs development. The choice of adopting this 
approach was connected to the difficulty in attributing these events to the right 
treatments, given the high rate of treatment changes and the potential contribution 
of previous therapies on response achievement. However, this approach could limit 
the lifelikeness of the obtained results. Sixth, adherence to treatments could not be 
evaluated.  A systematic review by Noens et al 219 reported that non-adherence is 
common among CML patients, mainly due to drug-related AEs and forgetfulness, 
and is associated with critical outcomes; however, data on comparative adherence 
to different TKIs are lacking. Therefore, our results on treatment effectiveness may 
have been influenced by a poor and different adherence to imatinib and nilotinib. 
Seventh, underreporting and underestimation of milder AEs could be present, since 
only acute events leading to hospitalizations or emergency room attendances, or 
patients’ self-reported AEs recorded by physicians were captured. Eighth, patients 
may be co-followed up by different hospitals and physicians at the same time; 
therefore, examined PPR and local administrative databases might not be complete, 
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due to information recorded in other hospital districts.  Finally, this study could not 
take into account the quality of life experienced by patients on different treatments, 
given that data on patients’ perceptions and satisfaction with treatment were not 
recorded on PPR. Considering that few data on patients’ quality of life are available 
in literature and given the long term duration of CML treatment, further research is 
worth of been conducted in this area.   
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5. CONCLUSION 
Progress in treatment of CML has been going on so rapid, that any recommendation 
on the management of CML can quickly become obsolete 70. 
Nevertheless, increasing knowledge from the routine clinical practice represents 
a key strategy in the life-long fighting of this disease, which has now become 
chronic. 
Despite the above-mentioned limits, this study represents an unbiased reference 
on the long-term management of CML in an Italian clinical setting, providing 
important real-world evidence on therapeutic patterns and effectiveness of TKIs. 
Our results indicate a superiority of nilotinib as first line therapy for CP-CML, both 
in terms of effectiveness and of treatment switches and AEs occurrence. While this 
might be seen as an argument to use nilotinib first line, it might also argue strongly 
for the continued use of imatinib first line, reserving nilotinib for imatinib intolerant 
or resistant patients. This is particularly true as the first generic imatinib is about to 
be launched, thereby increasing the already high difference in costs for the NHS 
between imatinib and nilotinib. A full health economic evaluation is required to 
determine the most cost effective care pathways using these expensive drugs.  
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